Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2013		Aug. 31, 2012
Cash flows from operating activities:
Net loss	$ (57,325)		$ (27,211)
Adjustments to reconcile net loss to net cash used in operating activities:
Employee stock-based compensation expense	5,417		3,570
Consultant stock-based compensation expense	3		72
Fair value adjustment of common stock warrants	12,025		(995)
Amortization of intangible assets	134		109
Depreciation of fixed assets	152		32
Realized (gain) on sale of fixed assets	(12)		0
Realized (gain) loss on short-term investments	129		(215)
Unrealized (gain) on short-term investments	0		(33)
Amortization of debt issuance costs	289		0
Amortization of deferred offering costs	373		32
Write-off of intangible assets and other intellectual property	0		900
Changes in assets and liabilities:
Accounts receivable, net	(5,519)		0
Inventories, net	(2,218)		0
Prepaid expenses and other	(1,154)		(2,781)
Intangible assets	(1,250)		0
Deposits	(127)		0
Accounts payable	(2,752)		(664)
Accrued liabilities	7,110		994
Deferred revenue	3,010		0
Deferred rent	151		(7)
Net cash used in operating activities	(41,564)		(26,197)
Cash flows from investing activities:
Purchase of fixed assets	(1,060)		(364)
Sale of fixed assets	27		0
Change in restricted cash	(337)		(56)
Purchase of short-term investments	(147)		(15,040)
Sale of short-term investments	22,114		30,000
Net cash provided by investing activities	20,597		14,540
Cash flows from financing activities:
Proceeds from the sale of common stock under an ATM sales agreement	39,964		7,684
Proceeds from the exercise of common stock warrants	9,809		3,057
Proceeds from the exercise of common stock options	1,516		325
Note payable	25,000		0
Fundraising costs	(1,572)		(360)
Debt issuance costs	(1,259)		0
Deferred offering costs	(436)		(166)
Capital lease, net	44		8
Net cash provided by financing activities	73,066		10,548
Effect of exchange rates on cash and cash equivalents	(78)		(43)
Net increase (decrease) in cash and cash equivalents	52,021		(1,152)
Cash and cash equivalents, beginning of period	36,313	[1]	24,732
Cash and cash equivalents, end of period	88,334		23,580
Supplemental cash flow information:
Interest paid	2,314		3
Supplemental disclosure of non-cash financing activities:
Fair value of warrant liability reclassified to equity upon exercise	$ 18,091		$ 7,106

[1] Derived from the Company's audited consolidated financial statements as of December 31, 2012.